It is a therapy with low doses of chemotherapy using insulin as a biological response modifier therapy is known as insulin potentiation therapy (IPT) . It is an innovative cancer treatment that allows the use of chemotherapy drugs selected according to the accepted oncology practice. These medications are administered in much lower than what is accepted as the standard dose.
The efficacy of the lower dose is based on the physiological and clinical evidence to get better by the use of insulin for transporting chemotherapy drugs through the cell membrane in cancer cells experience. Insulin acts on the bio-physical-chemical aspects of cell membrane allowing carry introduce chemotherapy drugs attack cancer cells first. Clinical experience also suggests strongly that this protocol minimizes the side effects associated with chemotherapy. The most notable impact is reported by patients improved quality of life.
IPTLD medical practitioners use approximately from a tenth to a quarter of the dose of conventional chemotherapy drugs. In addition, clinical experience and some studies suggest that the use of insulin as a biological response modifier allows this fractional doses can produce clinically significant tumor responses.
There may be some side effects. Some patients have nausea, sometimes they experiment it for a few hours after the first few treatments, but this can be easily handled. Occasionally, white blood cells, red blood cells and platelets may decrease, but not in the same ranges of conventional therapy.
IPTLD treatments can work well for many different types of cancer. Many reports have shown that therapy can bring responses and remissions in patients with some types of difficult cancer, even in later stages. It is important to note, however, that each patient is evaluated by type of cancer, stage of cancer development when presented for treatment, and the virulence of the individual patient’s cancer cells, and other relevant factors.
IPTLD treatment is administered in the same manner as conventional chemotherapy. The patient will be comfortably in a reclining chair and low-dose chemotherapy is received through an IV. The treatment can last about an hour and a half, and will be monitored at all times during application.
The number of treatments depends on each patient’s medical profile and how well they respond. The frequency of treatment will also vary with each patient.